drugset / Trial / NCT02249936

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

NCT02249936

Phase 1 Completed 18 enrolled Ardelyx AstraZeneca · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of different formulations of AZD1722 in healthy male and female subjects taking Omeprazole.

Timeline

Start
2013-02
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenapanor Small molecule 15 mg
Background Omeprazole Other / unclassified 20 mg

Indications

No indication recorded.